Related Experiment Video
Updated: Jul 19, 2026
06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
Extended-release carbamazepine (Equetro) for bipolar disorder
The Medical Letter on Drugs and Therapeutics
|March 30, 2005
Summary
Equetro, an extended-release carbamazepine formulation, is approved for acute mania and mixed episodes in bipolar disorder. While effective short-term, it is not recommended for maintenance therapy and shows no superior efficacy to existing treatments like lithium or valproate.
Area of Science:
- Pharmacology
- Psychiatry
- Neurology
Background:
- Carbamazepine extended-release formulation approved for epilepsy since 1997.
- New approval for Equetro (carbamazepine) targets acute mania and mixed episodes in bipolar disorder.
Purpose of the Study:
- To evaluate the efficacy and safety of Equetro for acute mania and mixed episodes of bipolar disorder.
- To assess the suitability of carbamazepine for maintenance treatment in bipolar disorder.
Main Methods:
- Clinical trial data assessing carbamazepine's effectiveness in bipolar disorder patients.
- Comparison of carbamazepine efficacy against established treatments like lithium and valproate.
Main Results:
- Equetro demonstrated effectiveness in treating acute mania and mixed episodes for up to six months.
- Carbamazepine did not prove more effective than lithium or valproate.
- Serious adverse effects associated with carbamazepine use were noted.
Conclusions:
- Equetro is a viable option for short-term treatment of acute mania and mixed episodes in bipolar disorder.
- Carbamazepine is not indicated for maintenance therapy in bipolar disorder.
- Clinicians should weigh the potential serious adverse effects against the benefits of carbamazepine compared to other mood stabilizers.
Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...